The company is planning to submit an investigational new drug (IND) application to the FDA later 2008 to commence a Phase I clinical trial for its cancer stem cell vaccine product, ICT-111, to treat glioblastoma. The company’s cancer stem cell vaccine technology also could be applicable for multiple other cancers.
Manish Singh, president and CEO of IMUC, said: “We are excited about the data we have observed from the preclinical studies demonstrating a highly specific and potent immune response against cancer stem cells, as well as a survival advantage in the animals tested in preclinical studies.”